FDA adds an­oth­er drug OK to cap a record win list for 2021

With the clock tick­ing through the fi­nal hours of an event­ful 2021, FDA reg­u­la­tors took the op­por­tu­ni­ty to squeeze in one more drug ap­proval.

This time the nod went to Xeris for a rare dis­ease treat­ment known as le­voke­to­cona­zole, now ap­proved for sale as Recor­lev. The drug is de­signed to treat hy­per­cor­ti­solemia in pa­tients suf­fer­ing from Cush­ing’s syn­drome. In late stage stud­ies, re­searchers tracked a drop and nor­mal­iza­tion in cor­ti­sol lev­els in pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER